Zagreb’s Optimapharm takes over Czech MKS Research

After the takeover, Optimapharm will have 120 employees and annual business income of over €12 million. Optimapharm is the regional leader in the field of clinical research (Clinical Research Organization – CRO), and the takeover of MKS Research, i.e. its entry into Czech market, will additionally strengthen the portfolio of clients from the pharmaceutical and biotechnological industry and the company’s market position in Central Europe.

This move is in accordance with this Croatian company’s mid-term strategic goal to become the biggest independent clinical research organization in Central and Eastern Europe, and with operations across Europe and USA. Value of global market of clinical research over the past years has increased at annual rates of over 10 per cent, and in 2016 it reached the amount of $31.4 billion. Forecasts say that it will reach the sum of $49.26 billion in the period from 2017 to 2021.